PERTH, Australia – Melbourne-based regenerative medicine company Cynata Therapeutics Ltd. is gearing up to take its Cymerus mesenchymal stem cell (MSC) product candidate CYP-001 into phase II trials after reporting solid results in two cohorts of patients in its phase I trial in steroid-resistant graft-vs.-host disease (GvHD).
PERTH, Australia – Melbourne-based regenerative medicine company Cynata Therapeutics Ltd. is gearing up to take its Cymerus mesenchymal stem cell (MSC) product candidate CYP-001 into phase II trials after reporting solid results in two cohorts of patients in its phase I trial in steroid-resistant graft-vs.-host disease.
PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. said its allogeneic mesenchymal precursor cell therapy showed an overall survival rate of 75 percent compared to an expected 30 percent survival rate in its pediatric phase III trial in acute graft-vs.-host disease (aGVHD) at 100 days.
PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. said its allogeneic mesenchymal precursor cell therapy showed an overall survival rate of 75 percent compared to an expected 30 percent survival rate in its pediatric phase III trial in acute graft-vs.-host disease (aGVHD) at 100 days.
PERTH, Australia – Melbourne-based Medicines Development for Global Health (MDGH) became the first not for profit company to register a drug through the FDA's tropical disease priority review program.
PERTH, Australia – Melbourne-based Medicines Development for Global Health (MDGH) became the first not for profit company to register a drug through the FDA's tropical disease priority review program.
